Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + Budigalimab in Advanced HCC
NCT05822752Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of livmoniplimab in hepatocellular carcinoma (HCC), sponsored by AbbVie Inc.. Started Sep 2023; status: active, not recruiting.
02
Drugs
livmoniplimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05822752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822752.